MRK Share Price | Merck & Co., Inc. Stock Analysis & Recommendation

Q: What does Merck & Co., Inc. do?

Overview:Merck & Co., Inc. is a global healthcare company operating in the Pharmaceuticals & Biotechnology industry, offering health solutions through prescription medicines, vaccines, biologic therapies, and animal health products.Financial Snapshot:Most recent Net Sales: 15,619 Million (Quarterly Results - Mar 2025) Most recent Net Profit: 5,085 Million (Quarterly Results - Mar 2025) Market-cap: USD 278,896.88 Million (Large Cap)Key Metrics:P/E: 15.00 Dividend Yield: 5.82% Debt Equity: 0.53 Return on Equity: 40.02% Price to Book: 5.77 Contact Details:Address: 2000 Galloping Hill Rd, KENILWORTH NJ: 07033-1310 Tel: 1 908 7404000 Website: http://www.merck.com/

Q: Who are in the management team of Merck & Co., Inc.?

As of March 2022, the management team of Merck & Co., Inc. includes Mr. Kenneth Frazier, who serves as the Chairman of the Board, President, and Chief Executive Officer. Additionally, the board features Mr. Leslie Brun as the Lead Independent Director, along with independent directors Dr. Thomas Cech, Ms. Mary Coe, Ms. Pamela Craig, and Mr. Thomas Glocer.

Q: Is Merck & Co., Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Merck & Co., Inc. moved from fair to attractive, indicating a positive shift in its perceived value. The company appears to be undervalued given its P/E ratio of 15, which is lower than the peer average of approximately 26.1 for comparable companies like Johnson & Johnson and Eli Lilly & Co. Additionally, Merck's PEG ratio stands out at 0.03, suggesting strong growth potential relative to its price, while its EV to EBITDA ratio of 11.50 is competitive against peers like Pfizer, which has an EV to EBITDA of 11.07.In terms of performance, Merck's recent stock returns have lagged behind the S&P 500, with a year-to-date decline of 14.77% compared to the index's gain of 13.30%. This underperformance, coupled with a robust ROE of 40.02% and a dividend yield of 5.70%, reinforces the narrative that Merck is currently undervalued in the market.

Q: Is Merck & Co., Inc. technically bullish or bearish?

As of 31 October 2025, the technical trend for Merck & Co., Inc. has changed from mildly bearish to mildly bullish. The current stance is mildly bullish, driven by a mildly bullish MACD on the daily timeframe and mildly bullish moving averages. However, the weekly MACD is mildly bullish while the monthly MACD remains bearish, indicating mixed signals across different timeframes. Additionally, the Dow Theory shows a mildly bearish signal on the weekly chart but is mildly bullish on the monthly chart. In terms of performance, Merck has underperformed the S&P 500 across multiple periods, with a year-to-date return of -15.70% compared to the S&P 500's 16.30%, and a one-year return of -17.69% versus 19.89% for the index.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

2.15 M

Shareholding (Dec 2025)

FII

17.96%

Held by 716 FIIs

DII

49.83%

Held by 238 DIIs

Promoter

0.13%

How big is Merck & Co., Inc.?

22-Jun-2025

As of Jun 18, Merck & Co., Inc. has a market capitalization of $278.9 billion, with net sales of $63.8 billion and net profit of $17.5 billion over the latest four quarters.

View full answer

What does Merck & Co., Inc. do?

22-Jun-2025

Merck & Co., Inc. is a global healthcare company that provides prescription medicines, vaccines, biologic therapies, and animal health products. As of March 2025, it reported net sales of $15.6 billion and a market cap of approximately $278.9 billion.

View full answer

Who are in the management team of Merck & Co., Inc.?

22-Jun-2025

As of March 2022, Merck & Co., Inc.'s management team includes Kenneth Frazier as Chairman, President, and CEO, and Leslie Brun as Lead Independent Director, along with independent directors Thomas Cech, Mary Coe, Pamela Craig, and Thomas Glocer.

View full answer

Is Merck & Co., Inc. overvalued or undervalued?

20-Oct-2025

As of October 17, 2025, Merck & Co., Inc. is considered undervalued with a P/E ratio of 15 compared to the peer average of 26.1, a strong growth potential indicated by a PEG ratio of 0.03, and a competitive EV to EBITDA ratio of 11.50, despite recent stock underperformance and a robust ROE of 40.02% and dividend yield of 5.70%.

View full answer

Is Merck & Co., Inc. technically bullish or bearish?

05-Nov-2025

As of October 31, 2025, Merck & Co., Inc. shows a mildly bullish trend on daily and weekly charts, despite mixed signals from MACD indicators and underperforming the S&P 500 with year-to-date and one-year returns of -15.70% and -17.69%, respectively.

View full answer

Compare Merck & Co., Inc. with Similar Stocks

AbbVie, Inc.Johnson & Johnson Eli Lilly & Co.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

High Management Efficiency with a high ROCE of 22.52%

Strong ability to service debt as the company has a low Debt to EBITDA ratio of 1.58 times

The company has declared Positive results for the last 4 consecutive quarters

With ROCE of 29.98%, it has a attractive valuation with a 4.16 Enterprise value to Capital Employed

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 406,795 Million (Large Cap)

P/E

18.00

Industry P/E

Dividend Yield

5.15%

Debt Equity

0.45

Return on Equity

0.00%

Price to Book

0.00

Revenue and Profits:

Net Sales:

16,324 Million

(Quarterly Results - Dec 2025)

Net Profit:

2,962 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

3.44%

6 Months

27.9%

1 Year

40.16%

2 Years

-11.89%

3 Years

-3.48%

4 Years

32.29%

5 Years

43.68%

Merck & Co., Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

6.33%

EBIT Growth (5y)

19.58%

EBIT to Interest (avg)

14.83

Debt to EBITDA (avg)

1.58

Net Debt to Equity (avg)

0.53

Sales to Capital Employed (avg)

6,500.89

Tax Ratio

13.47%

Dividend Payout Ratio

45.05%

Pledged Shares

Institutional Holding

80.78%

ROCE (avg)

22.52%

ROE (avg)

31.91%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

EV to EBIT

15.20

EV to EBITDA

13.56

EV to Capital Employed

EV to Sales

6.26

PEG Ratio

0.84

Dividend Yield

5.15%

ROCE (Latest)

ROE (Latest)

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bearish

Bollinger Bands

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

No Trend

Mildly Bearish

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 281 Schemes (32.02%)

Foreign Institutions

Held by 716 Foreign Institutions (17.96%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -5.00% vs 8.75% in Sep 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -48.82% vs 30.69% in Sep 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "16,324.00",
          "val2": "17,183.00",
          "chgp": "-5.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "8,626.00",
          "val2": "8,535.00",
          "chgp": "1.07%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "411.00",
          "val2": "327.00",
          "chgp": "25.69%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-2,567.00",
          "val2": "-711.00",
          "chgp": "-261.04%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "2,962.00",
          "val2": "5,787.00",
          "chgp": "-48.82%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "377.40%",
          "val2": "434.30%",
          "chgp": "-5.69%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 1.49% vs 6.85% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 6.60% vs 4,444.56% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "64,926.00",
          "val2": "63,973.00",
          "chgp": "1.49%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "29,324.00",
          "val2": "25,143.00",
          "chgp": "16.63%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1,357.00",
          "val2": "1,271.00",
          "chgp": "6.77%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1,704.00",
          "val2": "-1,179.00",
          "chgp": "-44.53%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "18,263.00",
          "val2": "17,133.00",
          "chgp": "6.60%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "361.70%",
          "val2": "322.70%",
          "chgp": "3.90%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

16,324.00

17,183.00

-5.00%

Operating Profit (PBDIT) excl Other Income

8,626.00

8,535.00

1.07%

Interest

411.00

327.00

25.69%

Exceptional Items

-2,567.00

-711.00

-261.04%

Consolidate Net Profit

2,962.00

5,787.00

-48.82%

Operating Profit Margin (Excl OI)

377.40%

434.30%

-5.69%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is -5.00% vs 8.75% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is -48.82% vs 30.69% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

64,926.00

63,973.00

1.49%

Operating Profit (PBDIT) excl Other Income

29,324.00

25,143.00

16.63%

Interest

1,357.00

1,271.00

6.77%

Exceptional Items

-1,704.00

-1,179.00

-44.53%

Consolidate Net Profit

18,263.00

17,133.00

6.60%

Operating Profit Margin (Excl OI)

361.70%

322.70%

3.90%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 1.49% vs 6.85% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 6.60% vs 4,444.56% in Dec 2024

All Annual Results

Company CV

About Merck & Co., Inc.

Merck & Co., Inc.

Pharmaceuticals & Biotechnology

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices.

Company Coordinates

Company Details

2000 Galloping Hill Rd , KENILWORTH NJ : 07033-1310

Tel: 1 908 7404000

http://www.merck.com/

Registrar Details